source
- Zealand Pharma shares tumble 12% after Boehringer obesity drug trial meets endpoints but disappoints analystsA phase 3 trial of Boehringer Ingelheim's dual‑agonist drug survodutide in people with obesity and type 2 diabetes was presented at the European Association for the Study of Diabetes meeting in Mil…
- Final Medicare rule to curb doctor-administered drug prices covers only four firms, delivering far less savings than proposedThe Trump administration released a final rule intended to lower Medicare prices for drugs given in doctors' offices. The rule applies only to four pharmaceutical companies, a far narrower scope t…STAT · 20d agoRegulatoryNegative